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Triclosan (TCS) is a synthetic, chlorinated phenolic antimicrobial agent commonly used in commercial and healthcare products.
Items made with TCS include soaps, deodorants, shampoos, cosmetics, textiles, plastics, surgical sutures, and prosthetics. A
wealth of information obtained from in vitro and in vivo studies has demonstrated the therapeutic effects of TCS, particularly
against inflammatory skin conditions. Nevertheless, extensive investigations on the molecular aspects of TCS action have
identified numerous adversaries associated with the disinfectant including oxidative injury and influence of physiological
lifespan and longevity. This review presents a summary of the biochemical alterations pertaining to TCS exposure, with special
emphasis on the diverse molecular pathways responsive to TCS that have been elucidated during the present decade.
1. Introduction
Triclosan (TCS), or 5-chloro-2-(2,4-dichlorophenoxy)phe-
nol, is a synthetic broad-spectrum antimicrobial developed
in the 1960s. As a polychlorinated bisphenolic compound,
TCS has a perceptible aromatic odor and is weakly soluble
in water. It dissolves well in organic solvents including etha-
nol, dimethylsulfoxide (DMSO), and methanol [1], and the
type of solvent and detergent availability seem to influence
TCS activity [2–4]. For example, TCS dissolved in oils (e.g.,
olive oil) and alkali (e.g., sodium carbonate) exhibits mark-
edly reduced efficacy when compared to other solvents such
as glycerol and polyethylene glycol (PEG) [3, 5]. In fact, using
propylene glycol (PG) as a solvent renders TCS more
effective than using PEG, which is probably due to micellar
solubilization of TCS in the larger PEG molecules [3].
Recently, we have shown that the presence of nonionic
detergents (e.g., Tween 20) inhibits TCS activity in vivo, most
likely due to micelle formation [6]. In contrast, sodium
dodecyl sulfate (SDS) has been reported to potentiate the
antibacterial effect of TCS in vitro [7].
TCS has gained enormous popularity in commerce
and in healthcare owing to its antibacterial, antiviral,
and antifungal properties [8–10]. This efficacy has led to
the widespread use of TCS as a preservative in a variety
of consumer products, including cosmetics, soaps, mouth-
washes, antiperspirants, kitchen utensils, clothing textiles,
bedclothes, electronics, plastics, and toys (Triclosan White
Paper prepared by the Alliance for the Prudent Use of
Antibiotics (APUA)). In clinical practice, TCS is used as
a disinfectant and an antiseptic in surgical sutures, scrubs,
implants, and medical devices [11, 12]. Annual global
production of TCS was estimated at 1500 tons [13], and
a total of 132 million liters of TCS-containing products
was consumed in a single year in the United States
(Safety and Effectiveness of Consumer Antiseptics; Topi-
cal Antimicrobial Drug Products for Over-the-Counter
Human Use; Proposed Amendment of the Tentative
Final Monograph. 2013 https://www.fda.gov/downloads/
AboutFDA/ReportsManualsForms/Reports/EconomicAnalyses/
UCM379555.pdf).
The high demand for TCS has consequently led to
substantial buildup in drinking and wastewater sources and,
more alarmingly, accumulation in body fluids [14–20],
establishing the antimicrobial as an environmental pollutant.
Pharmacokinetic studies in man show that TCS reaches the
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systemic circulation by rapid absorption through the skin
and mucous membranes of the oral cavity and gastrointesti-
nal tract, and variations in the bioavailability of TCS unsur-
prisingly affect the rate of urinary excretion [21, 22]. TCS
content in commercial products may reach as high as
17mM and comprise up to 1% of ingredients [12, 19, 23].
Moreover, absorption of up to 25% of applied TCS has been
recorded [24], and metabolic studies in rats and mice
revealed sulfation, glucuronidation, and hydroxylation prod-
ucts in tissues and excreta [25, 26].
Since the advent of TCS, early studies on the antiseptic
have shown evidence of symptomatic relief from acne
[27, 28] and contact dermatitis [29, 30] with fewer, or at
least comparable, side effects to other therapeutic alternatives
[31]. Later, TCS was found to be effective against crural ulcer
[32] and chemically induced dermatitis and desquamation
[33, 34], which could be attributed to its anti-inflammatory
[35], hypoallergenic [36], and analgesic [37] properties.
Moreover, a battery of studies collectively indicate that TCS
is not a skin or oral mucosal irritant, has a very low sensitiza-
tion potential (0.1-0.3% of 14,000 subjects), and is unlikely to
be phototoxic to human skin (http://ec.europa.eu/health/
ph_risk/committees/04_sccp/docs/sccp_o_166.pdf). This is
in contrast to the reversible skin and eye irritation caused
by up to 10% TCS reported in animals (http://ec.europa.eu/
health/ph_risk/committees/04_sccp/docs/sccp_o_166.pdf).
Also, in initial studies by Lyman and Furia, it was suggested
that TCS is carcinogenic when orally administered to rats
[38, 39]. Subsequent investigations in rats and mice disclosed
that TCS perturbs microsomal detoxification [40], causes
nephrotoxicity and hepatotoxicity [41], reduces prenatal
and postnatal survival [42], and leads to central nervous
system suppression [43] and hypothermia [44]. In humans,
the earliest description of an adverse TCS reaction probably
comes from a case report of two patients who developed
contact dermatitis following application of deodorants con-
taining 0.12% and 0.2% TCS [45]. Since then, several case
reports of the same ailment have thus far been in congruence
[46–49]. It is important to mention that, as is the case with
healthy subjects, in patients diagnosed with, or suspected to
have, contact dermatitis, TCS was similarly found to have a
very low sensitization potential (0.6-0.8% of 11,887 patients)
(http://ec.europa.eu/health/ph_risk/committees/04_sccp/
docs/sccp_o_166.pdf).
In light of the dichotomous debate surrounding TCS, the
US Food and Drug Administration (FDA), following exten-
sive examination of available data, has effectively banned
antiseptic products containing TCS since September 2016
[19]. In Europe, TCS was approved for use in cosmetics by
the European Community Cosmetic Directive in 1986
(http://ec.europa.eu/health/ph_risk/committees/04_sccp/
docs/sccp_o_166.pdf). However, the European Commis-
sion disapproved the use of TCS for hygienic purposes in
2017, but maintained its legality as a preservative in
select cosmetics and mouthwashes in concentrations up
to 0.3% and 0.2%, respectively (http://ec.europa.eu/health/
scientific_committees/consumer_safety/docs/sccs_o_054.pdf;
http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=
OJ:L:2014:107:FULL&from=EN). Furthermore, the Scientific
Committee on Consumer Safety (SCCS) expressed its
concern over the continued use of TCS in cosmetics, but
not in antiseptics, mainly due to the cumulative pattern of
exposure (http://ec.europa.eu/health/scientific_committees/
consumer_safety/docs/sccs_o_054.pdf). Importantly, the
European Chemicals Agency (ECHA) classifies TCS, under
the classification, labeling, and packaging (CLP) regulation,
as an eye irritant 2 (causes serious eye irritation), skin irritant
2 (causes skin irritation), aquatic acute 1 (very toxic to aquatic
life), and aquatic chronic 1 (very toxic to aquatic life with
long-lasting effects) (https://echa.europa.eu/documents/10162/
21680461/bpc_opinion_triclosan_pt1_en.pdf/efc985e4-8802-
4ebb-8245-29708747a358). Because of the previously men-
tioned ecotoxic properties, TCS is currently a candidate
for substitution under the Biocides European Union






Our aim in this review is to provide an update on current
knowledge regarding TCS therapeutic and toxic potential.
Emphasis is placed on the biochemical and molecular
alterations, either brought about by, or in response to, TCS
exposure. Data from both in vitro and in vivo studies,
obtained from humans and other organisms, are incorpo-
rated into the analysis, with special attention being given to
reports published during the present decade.
2. Membrane and Cytoskeletal Damage
Perhaps the earliest report describing the antimicrobial activ-
ity of TCS was by Vischer and Regös [50] which was shown
through topical application. In a follow-up study, TCS was
found to be more effective with the broadest spectrum
against bacteria and fungi when compared to other antimi-
crobials such as gentamicin and clotrimazole [10]. Subse-
quent efforts, which continue to this day, have focused on
dissecting the diverse action mechanisms and cellular targets
of TCS. Initially, it was thought that TCS interacts with the
prokaryotic cell membrane nonspecifically [9]. This was cor-
roborated by the resistance of Gram-negative bacteria to
TCS, which was ascribed to their outer membrane [51, 52].
Investigating the genetic response ofMycobacterium tubercu-
losis to TCS, Betts et al. [53] identified perturbations in a wide
assortment of genes involved in cell wall, transport, detoxifi-
cation, and DNA replication and transcription. Also, Klebsi-
ella pneumoniae with inactive efflux pump KpnGH exhibit
pronounced susceptibility to multiple antibiotics including
TCS [54]. Several genes in the membrane stress response
pathway were also studied in Escherichia coli and Rhodospir-
illum rubrum S1H [55–57]. During the electro-Fenton
transformation of TCS, significant changes in expression
patterns of genes involved in cell wall and membrane
structure, cell envelope, flagella, and multidrug efflux were
observed (Table 1). These findings complement an earlier
report describing enhanced resistance to TCS due to overex-
pressed acrAB multidrug efflux pump [58]. It was recently
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suggested that TCS binds to the transcriptional repressor
AcrR, causing conformational changes and preventing its
binding to the efflux pump AcrA promoter in Agrobacterium
tumefaciens [59].
The interaction of TCS with the cell membrane was also
studied in human red blood cells (RBCs; erythrocytes). TCS
exposure led to K+ leakage and overt hemolysis, indicating
membrane damage, while antagonizing hypotonic lysis,










acrE Upregulated by TCS
mdtE Upregulated by TCS
acrF Upregulated by TCS
mdtB Upregulated by TCS
mdtC Upregulated by TCS
yddA Upregulated by TCS
emrA Upregulated by TCS








clsA Upregulated by TCS




flgM Upregulated by TCS
R. rubrum S1H
sugE Small multidrug resistance protein Upregulated by TCS
mexF
RND efflux system, inner membrane transporter
Upregulated by TCS
mexB Upregulated by TCS
mexE
RND efflux system, membrane fusion proteins
Sensitive to TCS
mexA Upregulated by TCS
mexM Upregulated by TCS
oprM RND efflux system, outer membrane transporter Upregulated by TCS
glmM Cell envelope; phosphoglucosamine mutase Upregulated by TCS
exoD Cell envelope; exopolysaccharide synthesis protein D Upregulated by TCS
wbpM Cell envelope; polysaccharide biosynthesis protein M Upregulated by TCS
A. tumefaciens C58 AcrA RND efflux system, periplasmic adaptor protein Upregulated by TCS
Human erythrocytes Na+,K+,Mg2+-ATPase Membrane ion transporter Sensitive to TCS





Actin α1, skeletal muscle Downregulated by TCS
Light polypeptide 3 Downregulated by TCS
Desmin
Cytoskeleton; muscular filament structure
Upregulated by TCS
Fast skeletal muscle myosin Sensitive to TCS
Keratin, type I cytoskeletal 18 Upregulated by TCS
Tropomyosin α-1 chain Downregulated by TCS
Type II cytokeratin Upregulated by TCS





Tubulin β-4 chain Upregulated by TCS
Myosin light chain Cytoskeleton; muscular filament structure Upregulated by TCS
Abbreviation: RND: resistance-nodulation-division; ABC: ATP-binding cassette.
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which may be due to membrane expansion [60]. TCS also
inhibited membrane-bound Na+,K+,Mg2+-ATPase enzy-
matic activity [61]. These observations suggest that TCS
causes membrane destabilization, perturbs monovalent ion
transport, and modulates the overall osmoregulation of
erythrocytes. Evidence for membrane damage is further
confirmed in numerous studies by means of compromised
stability and permeability [62]. To directly observe how
TCS interacts with the cell membrane, Guillén and
coworkers utilized nuclear magnetic resonance (NMR)
spectroscopy to demonstrate that TCS intercalates within
hydrophobic pockets in the lipid bilayer, perpendicularly
to phospholipid molecules [63]. Furthermore, using neu-
tral red to evaluate membrane integrity, diminished uptake
of the dye in hemocytes of the clam Ruditapes philippi-
narum and mussel Mytilus galloprovincialis was related
to TCS-induced suppression of pinocytosis and disturbed
phagocytosis [64, 65].
Along those lines, our recent findings indicate that TCS
blunts the expression of the pmp3 membrane transporter in
Caenorhabditis elegans nematodes and that pmp3(ok1087)
mutants exhibit increased sensitivity to the disinfectant
[66]. Finally, a proteomic analysis of zebrafish (Danio rerio)
larvae and gills of freshwater mussel Dreissena polymorpha
revealed alterations in cytoskeletal protein levels following
TCS exposure (summarized in Table 1) [67, 68].
There is a consensus in the literature regarding the
membranotropic nature of TCS in different membrane
models across various species. The cell membrane is a pri-
mary target for TCS and among the first cellular obstacles
that must be overcome by the antiseptic to exert its effects.
Although evidence implicating membrane-associated efflux
pumps as part of the cellular response to TCS is strong, there
is paucity in reports describing TCS modulation of structural
or functional membrane components in human-based sys-
tems. Similarly lacking is an understanding of the role of
membrane receptors not only in pumping out TCS molecules
but also in transducing both inter- and intracellular signals as
a consequence to TCS presence.
3. Cellular Longevity
The interest in TCS and ultimate cell fate has originally
stemmed from its use in oral hygiene products, which is
reflected in two seminal studies on human gingival cells
[69, 70]. TCS was shown to be cytotoxic to gingival fibro-
blasts and epithelial cells, identifying it as a novel stimulator
of apoptosis in the latter.
Investigations have thus far followed a more comprehen-
sive approach, relating cell death induced by TCS to other
cellular adversaries, utilizing both human and non-human
model systems. When TCS was treated to human choriocar-
cinoma placental cells (JEG-3), multiple dose- and time-
dependent responses were observed [71]. While there was a
proportional increase in estradiol and progesterone secre-
tion, β-human chorionic gonadotropin (β-hCG) release
was nevertheless inhibited with increasing TCS concentra-
tions [71]. In addition to blunted proliferation, significant
cell death was recognized as apoptotic in nature evidenced
by activated caspase-3 and Hoechst 33342-stained fragmen-
ted DNA [71]. Similarly, using anoikis-resistant H460
human lung cancer cells, Winitthana et al. demonstrated that
24-hour exposure to 10μM TCS causes cell death and
apoptosis. Nontoxic levels (≤7.5μM), however, enhanced cell
growth (increased colony number and reduced size) without
altering proliferation. TCS also promoted epithelial-to-
mesenchymal transition (EMT), along with the migratory
and invasive abilities of the cells [72].
A research group performed a series of in vivo and
in vitro studies on the effect of TCS on growth and prolifera-
tion of human BG-1 ovarian cancer cells. Results from these
studies indicate that TCS increases cellular proliferation and
both gene expression and protein levels of cyclin D1 and
decreases p21 and Bax gene expression and protein levels
[73]. These effects were significantly antagonized by the
estrogen receptor (ER) antagonist ICI 182,780, implicating
ER in TCS-induced cell cycle progression and in its antiapop-
totic role. Investigators from the same group also reported a
similar response to TCS by MCF-7 breast cancer cells and
LNCaP prostate cancer cells. In MCF-7 cells, 1μM TCS
enhanced growth and proliferation during a six-day period,
which was associated with increased cyclin D1 and reduced
p21 expression levels. When mice were treated with TCS
for 8 weeks, brdU-positive breast tumor cells were signifi-
cantly increased compared to the control group treated with
corn oil [74]. Similar to BG-1 cells, TCS-promoted prolif-
eration of MCF-7 cells was mediated through ERα signaling,
demonstrated as antagonism by kaempferol and 3,3′-
diindolylmethane (DIM), two phytoestrogens [75]. In addi-
tion to cyclin D1 and p21, TCS caused an increase in cyclin E
and a decrease in Bax and induced metastasis through ele-
vated cathepsin D protein expression. These observations
were paralleled in vivo using xenografted mouse models.
Researchers from this report expanded their findings to
VM7Luc4E2 cells, a variant of the MCF-7 model, to show
that TCS (0.1-10μM) is pro-proliferative and antiapoptotic
by inhibiting oxidative stress, with both effects being antago-
nized by kaempferol [76]. In LNCaP cells exposed to concen-
trations of TCS ranging from 0.01 to 10μM for up to 5 days
showed enhanced proliferation and migration and reduced
p21 protein expression [77]. In primary human syncytiotro-
phoblasts, TCS at 0.001 to 10μM induced apoptosis as seen
by condensed nuclei and fragmented DNA [78]. TCS also
reduced 11β-hydroxysteroid dehydrogenase type 2 (11β-
HSD2) via a caspase-dependent mechanism. Other targets
included both Bax and Bcl-2 proteins.
Similar to human cells, both pro- and antiapoptotic prop-
erties were observed in rodent cells treated with TCS. Beside
its cytotoxicity, TCS caused caspase-dependent apoptosis in
rat neural stem cells along with elevated Bax and reduced
Bcl-2 [79]. In a series of studies, [80–82] mouse neurons were
used to show that TCS is apoptotic through the Fas receptor
(FasR), aryl hydrocarbon receptor (AhR), and caspase activa-
tion involving N-methyl-D-aspartate receptors (NMDARs).
In agreement with the cytotoxicity data, TCS-treated mouse
lung epithelial cells were deformed with reduced viability
[83]. Conversely, TCS stimulated the proliferation of mouse
epidermis-derived JB6 Cl 41-5a cells, by increasing cyclins
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D1 and A and reducing p27(Kip1) protein levels [84].
Examining these effects in vivo, B6C3F1 mice exhibited
epidermal hyperplasia and focal necrosis following topical
administration of TCS. Moreover, the pluripotency markers
of mouse embryonic stem cells were analyzed following
TCS exposure [85]. Alkaline phosphatase (Alp), Sox2,
Oct4, and Nanog were all reduced, while miRNA-134
was elevated.
Unlike human and rodent cells, in vivo and in vitro
studies on aquatic organisms uniformly agree that TCS is
solely proapoptotic in these animals. Pyknotic apoptosis in
the central nervous system of zebrafish D. rerio was observed
following treatment with either TCS alone or TCS combined
with derivatives 2,4,6-trichlorophenol (2,4,6-TCP) and 2,4-
dichlorophenol (2,4-DCP) [86, 87]. The TCS-derivative
mixture caused pronounced deformities and behavioral
abnormalities and perturbed the expression of a panel of
neurodevelopmental and apoptotic genes (Table 2). Also,
TCS, following both in vivo and in vitro exposure, induced
a dose- and time-dependent increase in apoptotic hemocytes
of D. polymorpha [88, 89]. Likewise, when the saltwater clam
Ruditapes philippinarum was treated with TCS, hemocytes
exhibited significant cell death, blunted proliferation,
reduced size, and promiment apoptotic DNA fragmentation
[65]. TCS-induced apoptosis, or apoptosis-like cell death,
was also detected in unicellular organisms, such as the green
alga Chlamydomonas reinhardtii and the pathogenic fungus
Cryptococcus neoformans [90, 91].
Collectively, studies on TCS influence on cell fate indi-
cate estrogenic, proliferative, and apoptotic activities.
Genes and proteins governing the regulation of cell cycle
and apoptosis are particularly sensitive to TCS modula-
tion. The disparity in ultimate cell fate seems to point at
an interspecies variation and a dose-specific response,
among other experimental details such as cell type and
duration of exposure. Elucidating the existence and the
identity of a specific molecular “switch” that may tip the
scales in favor of either cell death or survival could be
an important inquiry for future investigations.
4. Oxidative Stress
Overwhelming evidence has recently accumulated in support
of the prooxidative action of TCS. It is prudent to provide an
overview of human-based studies first before summarizing
notable findings obtained from other model organisms.
In Puerto Rican pregnant women, a correlation between
exposure to TCS during pregnancy and oxidative damage,
as measured by urinary 8-hydroxyguanosine (8-OHdG),
and inflammation was suggested [92]. Similar observations
were also mirrored in Chinese and Brazilian children
[93, 94]. Conversely, in a global effort comprising nine coun-
tries from Asia, Europe, and North America, no relation
between urinary TCS and 8-OHdG was established [95].
In vitro studies on human cells have also shed some light
on the oxidative potential of TCS. In peripheral blood mono-
nuclear cells (PBMC), 2,4-dichlorophenol (2,4-DCP)—a
product of TCS transformation—promoted reactive oxygen
species (ROS) generation, with subsequent lipid peroxidation
and protein carbonylation [96]. Similarly, TCS caused ele-
vated ROS in Nthy-ori 3-1 human follicular thyroid cells
[97] and lipid peroxidation in retinoblastoma (Y79 RB) cells
[98]. Our recent investigations on mesenchymal stem cells
also showed TCS interference with the activation of nuclear
factor (erythroid-derived 2)-like 2 (Nrf2), the “master regula-
tor” of detoxification, and its downstream targets, heme
oxygenase 1 (HO-1) and NAD(P)H dehydrogenase [quinone
1] (NQO-1) [66]. Consistently, TCS incorporated in mou-
thrinse did not exhibit antioxidant activity on fibroblasts
[99]. In contrast, TCS reduced ROS levels in VM7Luc4E2
cells, which contributed to its antiapoptotic activity in these
malignant breast cells [76].
Mitochondrial damage was also evident in multiple
mammalian cells including human PBMC and keratinocytes,
exposed to 3.5-350μM TCS [100]. At concentrations up to
100μM, TCS caused depolarization of mitochondrial mem-
brane, reduced oxidative phosphorylation, and suppressed
ATP synthesis. Weatherly et al. [101] utilized human
HMC-1.2 mast cells and primary keratinocytes to show that
TCS is a proton ionophore uncoupler and interferes with
ATP production.
Animal studies conducted on mice and rats have revealed
a profound response in the cellular antioxidant machinery
upon TCS treatment. In rat thymocytes, superoxide anions
were found to be elevated following TCS treatment [102]
which, as Yueh et al. [103] showed, was met with increased
expression of key antioxidant enzymes including HO-1,
NQO-1, and glutathione S-transferase (GST) in mouse liver.
Evidence for testicular DNA damage, elevated malondialde-
hyde (MDA), and superoxide dismutase (SOD), in addition
to diminished catalase (CAT), was related to TCS treatment
in weanling rats [104]. Similarly, in lung homogenates of
female albino rats, TCS was found to induce lipid peroxida-
tion and severely deplete the levels of other crucial antioxi-
dants: SOD, CAT, and glutathione (GSH) [105]. Increased
expression of glutathione peroxidase 1 (Gpx1) and aldehyde
oxidase 1 (Aox1) was also observed as a consequence to
TCS exposure in C57BL/6 mice [106]. Most recently, Zhang
et al. [97] showed downregulation of antioxidant enzymes,
Gpx3, Cat, and Sod2, along with elevated MDA, in the hypo-
thalamus of Sprague-Dawley rats. Moreover, it was found
that TCS treatment leads to increased ROS and reduced
GSH activity in rat neural stem cells [79]. TCS also increased
ROS levels in mouse neocortical neurons, along with per-
turbed regulation of cytochrome P450 family 1, subfamily
a, member 1 (CYP1a1) and CYP1b1 [81, 82]. Effects of TCS
on cytochromes and hepatic detoxification were also demon-
strated in Sprague-Dawley rats, showing increased levels of
UDP-glucuronosyltransferase 1-1 (Ugt1a), Ugt2b1, CYP1a1,
CYP1a2, CYP2b1, CYP3a1, and sulfotransferase family 1E
member 1 (Sult1e1) [97].
Several terrestrial organisms have been employed in
the study of TCS toxicology. Caenorhabditis elegans is
among the best-studied animal models due to its ease
of maintenance and high genetic homology to humans.
We have recently shown that TCS leads to overproduc-
tion of ROS, inhibition of nuclear translocation of protein
skinhead-1 (SKN-1) antioxidant transcription factor, and
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Major female sex hormones
Upregulated by TCS
Progesterone Upregulated by TCS
β-hCG Maintenance of pregnancy Downregulated by TCS





p21 Downregulated by TCS





Cyclin E Upregulated by TCS
p21 Downregulated by TCS




Cathepsin D Upregulated by TCS
MMP-9 Upregulated by TCS
MMP-2 Upregulated by TCS




Slug Upregulated by TCS
LNCaP p21 Cell cycle regulator Downregulated by TCS
Primary human syncytiotrophoblasts




Bax Upregulated by TCS
Bcl-2 Apoptosis regulator; antiapoptotic Downregulated by TCS




Bax Upregulated by TCS
Bcl-2 Apoptosis regulator; antiapoptotic Downregulated by TCS
Mouse neocortical neurons
GluN1
Ionotropic glutamate receptors; neurotransmission
Downregulated by TCS
GluN1 Downregulated by TCS
GluN2A Downregulated by TCS
GluN2A Downregulated by TCS
GluN2B Upregulated by TCS




Caspase-8 Upregulated by TCS
Caspase-9 Upregulated by TCS
Caspase-3 Upregulated by TCS
AhR Ligand-activated receptor; detoxification Upregulated by TCS




Cyclin A Upregulated by TCS
p27 Downregulated by TCS
B6C3F1 mice
Alp
Pluripotency markers; stem cell self-renewal and
differentiation regulators
Downregulated by TCS
Oct4 Downregulated by TCS
Nanog Downregulated by TCS
ALP Downregulated by TCS
Oct 4 Downregulated by TCS
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downregulation of gamma-glutamyl cysteine synthetase
(Gcs1) [66]. In a subsequent report, Skn1 expression was
found to be upregulated by TCS along with Sod1, Sod4,
heat shock proteins (Hsp)-3, -4, -16.2, and -70; and cyto-
chromes Cyp29A2 and Cyp34A9 (https://app.dimensions.
ai/details/publication/pub.1103154992#readcube-epdf). TCS
also enhanced nuclear translocation of stress-related factor
DAF-16, suggesting the occurrence of oxidative stress
[107]. In the Earthworm Eisenia fetida, oxidative damage
by TCS was manifested as a transient elevation in CAT
and GST enzymes, increased MDA, and DNA damage
[108]. In a follow-up study by the same group, SOD
was also increased and decreased by TCS depending on
the concentration used [109], a response mirrored by
CAT in the snail Achatina fulica [110]. In that study,
TCS caused diminished levels of SOD and peroxidase
(POD), along with elevated MDA, among other morpho-
logical anomalies.
The ubiquity of TCS in aquatic environments has made
animal models from that habitat the subject of extensive
investigations on TCS toxicity. Perhaps the most relevant
aquatic organism is the zebrafish D. rerio, owing to a strong
structural and molecular resemblance to humans. Elucidat-
ing the interaction between TCS and the antioxidant system
in ZFL liver cells, Zhou et al. [111] showed evidence of
induced CYP1A activity along with a general trend of
suppression in phase I and II detoxification enzymes. Ele-
vated MDA, along with perturbed homeostasis of GSH,
peroxiredoxin-2 (PRD-2), and HSPs, were observed in zebra-
fish larvae grown in the presence of TCS ([67, 87]).
TCS has been shown to induce MDA and cause
oscillations in CAT, ethoxyresorufin-O-deethylase (EROD),
erythromycin N-demethylase (ERND), and aminopyrine
N-demethylase (APND) in Daphnia magna [112]. More-
over, elevated amino acids, including glutamine, glutamate,
and proline, have been attributed to a general oxidative stress
state in daphnids [113]. Also, stress-related proteins, includ-
ing glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
and hsp-70, were modulated by TCS in D. polymorpha, in
addition to lipid peroxidation [68]. TCS exposure demon-
strated reduced oxyradicals and lipofuscin and elevated
oxidized glutathione (GSSG) in the digestive gland of swollen
river mussels Unio tumidus [114]. In Tigriopus japonicus
copepods treated with TCS, increased ROS, SOD, GST,
GPx, and GSH content was noted [115]. TCS also caused
perturbations in expressional profiles of Cyps, Sod, Gst, and
Cat proteins (Table 3) [115].
TCS treatment in the yellow catfish Pelteobagrus
fulvidraco revealed induced CAT, EROD, ERND, and APND
[116]. Expressional profiling of Cyp1a, Cyp3a, and Gst
showed both up- and downregulation depending on TCS
concentration and length of exposure, a pattern that was also
seen with MDA formation. When another catfish, Hetero-
pneustes fossilis, was treated with a cosmetic effluent rich in
TCS, increased SOD and CAT activities and reduced GSH,
GST, and GPx were noted [117].
Oxidative damage by TCS was also evident in the goldfish
Carassius auratus, as MDA, CAT, and GSH were elevated in
addition to a reduced total antioxidant capacity [118].






Nanog Downregulated by TCS
Sox 2 Downregulated by TCS





Nanog Downregulated by TCS
Sox2 Upregulated by TCS









Ngn1 Upregulated by TCS
Nrd Upregulated by TCS




Gap43 Upregulated by TCS
Gfap Downregulated by TCS
Mbp Downregulated by TCS
Abbreviation: Shha: sonic hedgehog a;Ngn1: neurogenin 1;Nrd: NeuroD; Elavl3: ELAV-like, neuron-specific RNA-binding protein 3;Gap43: growth-associated
protein 43; Gfap: glial fibrillary acidic protein; Mbp: myelin basic protein.
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Urinary 8-OHdG Oxidized deoxyguanosine; DNA damage Upregulated by TCS




ROS Upregulated by TCS
Lipid peroxidation Oxidized lipids Upregulated by TCS
Protein carbonylation Oxidized proteins Upregulated by TCS
Y79 RB cells Lipid peroxidation Oxidized lipids Upregulated by TCS
Human bone marrow-derived
mesenchymal stem cells




Nqo-1 Downregulated by TCS






HO-1 Upregulated by TCS
NQO-1 Upregulated by TCS
GST Upregulated by TCS
Weanling rats




CAT Downregulated by TCS
Female albino rat lung
homogenates




CAT Downregulated by TCS
GSH Downregulated by TCS
C57BL/6 mice liver
Gpx1 Antioxidant enzyme; glutathione homeostasis Upregulated by TCS
Aox1 Superoxide and hydrogen peroxide formation Upregulated by TCS
Sprague-Dawley rat
hypothalamus
MDA Oxidized lipid marker Upregulated by TCS




Sod2 Downregulated by TCS
Rat neural stem cells
ROS Metabolic oxygen by-products Upregulated by TCS
GSH Antioxidant Downregulated by TCS
Mouse neocortical neurons
ROS Metabolic oxygen by-products Upregulated by TCS
Cyp1a1
Cytochrome family enzymes; detoxification
Downregulated by TCS
CYP1a1 Downregulated by TCS
Cyp1b1 Downregulated by TCS
Cyp1b1 Upregulated by TCS
Sprague-Dawley rat liver
Cyp1a1 Upregulated by TCS
Cyp1a2 Upregulated by TCS
Cyp2b1 Upregulated by TCS
CYP2b1 Upregulated by TCS








Sult1e1 Upregulated by TCS
C. elegans




SKN-1 Downregulated by TCS









Sod1 Upregulated by TCS
Sod4 Upregulated by TCS
Hsp-3
Stress response; protein stabilization
Upregulated by TCS
Hsp-4 Upregulated by TCS
Hsp-16.2 Upregulated by TCS
Hsp-70 Upregulated by TCS
Cyp29A2
Cytochrome family enzymes; detoxification
Upregulated by TCS
Cyp34A9 Upregulated by TCS
DAF-16 Stress response Upregulated by TCS
E. fetida




GST Upregulated by TCS
SOD Sensitive to TCS to TCS
A. fulica
MDA Oxidized lipid marker Upregulated by TCS
CAT
Antioxidant enzymes
Sensitive to TCS to TCS
SOD Downregulated by TCS
POD Downregulated by TCS
ZFL liver cells CYP1A Cytochrome family enzyme; detoxification Upregulated by TCS
D. rerio larvae
GPx
Antioxidant enzymes; glutathione homeostasis
Upregulated by TCS
GR Downregulated by TCS
PRD-2 Antioxidant enzyme Downregulated by TCS
Hsp-5
Stress response; protein stabilization
Upregulated by TCS
Hsp-90 β Upregulated by TCS
D. magna
MDA Oxidized lipid marker Upregulated by TCS
CAT Antioxidant enzymes Sensitive to TCS to TCS
EROD
Detoxification enzymes
Sensitive to TCS to TCS
ERND Sensitive to TCS to TCS
APND Sensitive to TCS to TCS
Glutamine
Amino acids; markers of protein
oxidation/breakdown
Upregulated by TCS
Glutamate Upregulated by TCS
Proline Upregulated by TCS
D. polymorpha gills Hsp-70 Stress response; protein stabilization Sensitive to TCS to TCS
U. tumidus digestive gland
GAPDH Oxidoreductase; glucose metabolism Sensitive to TCS to TCS
GSSG Oxidized glutathione; antioxidant Upregulated by TCS
Oxyradicals Oxygen-containing radicals; prooxidants Downregulated by TCS
Lipofuscin Lysosomal pigment granules; toxicity marker Downregulated by TCS
T. japonicus
ROS Metabolic oxygen by-products Upregulated by TCS
Sod
Antioxidant enzymes
Sensitive to TCS to TCS
SOD Upregulated by TCS
Cat Sensitive to TCS to TCS
Gst variants
Antioxidants; glutathione homeostasis
Sensitive to TCS to TCS
GST Upregulated by TCS
GPx Upregulated by TCS
GSH Upregulated by TCS
Cyp3026a3
Cytochrome family enzymes; detoxification
Upregulated by TCS
Cyp3037a1 Upregulated by TCS







MDA Oxidized lipid marker Sensitive to TCS to TCS
CAT Antioxidant enzyme Upregulated by TCS




ERND Upregulated by TCS
APND Upregulated by TCS
Cyp1a
Cytochrome family enzymes; detoxification
Sensitive to TCS to TCS









GST Downregulated by TCS
GPx Downregulated by TCS
C. auratus




SOD Downregulated by TCS
GSH Antioxidant; glutathione homeostasis Upregulated by TCS
Brachionus koreanus
ROS Metabolic oxygen by-products Upregulated by TCS
Gst variants
Antioxidant enzyme; glutathione homeostasis
Sensitive to TCS to TCS
Gpx Sensitive to TCS to TCS
GST Upregulated by TCS
Sod
Antioxidant enzymes
Sensitive to TCS to TCS
Cat Sensitive to TCS to TCS
Cyp3042a1
Cytochrome family enzymes; detoxification
Sensitive to TCS to TCS
Cyp43a1 Sensitive to TCS to TCS
Hsp10
Stress response; protein stabilization
Sensitive to TCS to TCS
Hsp21 Upregulated by TCS
Hsp27 Upregulated by TCS
Hsp30 Sensitive to TCS to TCS
Hsp40 Sensitive to TCS to TCS
Hsp40h Sensitive to TCS to TCS
Hsp60 Sensitive to TCS to TCS
Hsp70 Upregulated by TCS
Hsc70 Upregulated by TCS
Hsp90α1 Sensitive to TCS to TCS
Hsp90α2 Sensitive to TCS to TCS
Hsp90β Sensitive to TCS to TCS
B. gargarizans liver
Sod Antioxidant enzyme Downregulated by TCS
Phgpx
Antioxidant enzyme; glutathione homeostasis
Downregulated by TCS
P. perezi larvae GST Upregulated by TCS
R. philippinarum digestive gland
MDA Oxidized lipid marker Upregulated by TCS
CAT
Antioxidant enzymes
Sensitive to TCS to TCS
SOD Sensitive to TCS to TCS
GPx variants
Antioxidant enzymes; glutathione homeostasis
Sensitive to TCS to TCS
GST Sensitive to TCS to TCS
GR Sensitive to TCS to TCS
EROD Detoxification enzyme Sensitive to TCS to TCS
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levels were recorded in the goldfish’s liver after TCS
treatment under a pH range of 6 to 9 [119]. The oxidative
potential of TCS was also evident in the rotifer Brachionus
koreanus, detected as ROS overproduction and enhanced
GST activity, in addition to transcriptional modulation of
cytochromes, antioxidant genes Gst, Gpx, Sod, and Cat and
chaperons (Table 3) [120]. Moreover, TCS inhibited Sod
and phospholipid hydroperoxide glutathione peroxidase
(Phgpx) expression in the liver of Bufo gargarizans tadpoles
[121] and induced GST in Pelophylax perezi frog larvae [122].
Sendra et al. [123] studied the combined effect of tita-
nium dioxide (TiO2) and a heterogeneous mixture of organic
compounds including TCS using the clam Ruditapes philip-
pinarum. Modulations in EROD, SOD, CAT, GPx, GST,
and GR enzyme activities were noted in the clam’s digestive
gland, in parallel with increased lipid peroxidation. TCS
exposure caused alterations in Cat, Sod, Gpx1, Gpx2, Gsta,
Hsp90bb, Hsp90ba, and Hsc70a genes in rainbow trout
Oncorhynchus mykiss [124]. Although in one report TCS
failed to elicit oxidative stress in the green algae Chlamydo-
monas reinhardtii [125], another report detected ROS
formation following TCS exposure [90], which was also most
recently confirmed by significantly increased MDA, down-
regulated Gpx, and upregulated Sod expression [126].
The antimicrobial nature of TCS makes bacteria an
appropriate target for mechanistic studies. Using Rhodospir-
illum rubrum S1H, Pycke et al. [57] detected upregulation in










Sod Upregulated by TCS
Gpx variants
Antioxidant enzymes; glutathione homeostasis
Upregulated by TCS
Gsta Upregulated by TCS
Hsp90bb
Stress response; protein stabilization
Upregulated by TCS
Hsp90ba Upregulated by TCS
Hsc70a Upregulated by TCS
C. reinhardtii
ROS Metabolic oxygen by-products Upregulated by TCS
MDA Oxidized lipid marker Upregulated by TCS
Sod Antioxidant enzyme Upregulated by TCS
Gpx
Antioxidant enzyme; glutathione homeostasis
Upregulated by TCS
R. rubrum S1H
Gpx Upregulated by TCS
GrxC
Antioxidant enzymes; glutathione homeostasis
Upregulated by TCS
TrxB Upregulated by TCS
OsmC Antioxidant enzyme Upregulated by TCS
DnaJ Heat shock protein; general stress marker Upregulated by TCS
RpoN
RNA polymerase factor sigma-54; general stress
marker
Downregulated by TCS
TerA Tellurite resistance protein A; general stress marker Upregulated by TCS
Psp variants Phage shock proteins; general stress markers Sensitive to TCS to TCS
ClpP




Heat-inducible transcription suppressor; general
stress marker
Upregulated by TCS
E. coli K12, MG1655
OxyR ROS sensor proteins Upregulated by TCS




Cat variants Upregulated by TCS
Ahp variants Antioxidant enzymes Upregulated by TCS
E. coli




SoxS Downregulated by TCS
YhcN Downregulated by TCS
Abbreviation: TrxB: thioredoxin; OsmC: peroxiredoxin osmotically inducible protein C-like. ∗Effects of 2,4-DCP, a by-product of TCS degradation.
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notably Gpx. In E. coli K12, MG1655, the electro-Fenton
transformation of TCS caused activation of genes related to
ROS sensing, along with reduced glutaredoxin (Grx), Sod,
Cat, and alkyl hydroperoxide reductase (Ahpr) [55]. Very
recently, ROS formation by TCS was associated with dimin-
ished expression of antioxidants in E. coli (Table 3), an event
that preceded mutagenesis and enhanced drug resistance in
that species [56]. TCS was also recently used to validate novel
self-luminescent bioreporter strains of Nostoc sp. PCC 7120
using Sod promoters [127].
Collectively, monumental evidence demonstrates the
prooxidant properties of TCS evident as both overproduction
of ROS and interference with the cellular antioxidant defen-
some. TCS is toxic in part by inducing oxidative damage in
a wide range of organisms and by targeting a defined cluster
of proteins in a fashion that is conserved among diverse
species. Nonetheless, the vast majority of data are collected
from non-human models, and, as is the case with other
toxicological reports of TCS, studies conducted on man or
human-derived tissues are severely lacking.
5. Immunity and Inflammation
TCS has, for a long time, been recognized as an effective
therapy for infectious dermatitis [29–31], and the observed
curative capacity of the compound was solely attributed to
its antimicrobial activity. It was not until the end of last
century that associations between TCS exposure and remis-
sion of noninfectious inflammation were made [33, 35, 36],
and the use of antibacterials as anti-inflammatory agents
has gained deserved attention during the past two decades.
For example, an appreciable number of antibiotics, including
macrolides and quinolones, have been shown to possess anti-
inflammatory activity [128–132]. Follow-up efforts have
successfully provided solid evidence for the direct interaction
of TCS with inflammatory pathways.
Gaffar et al. [133] reported that TCS inhibits
cyclooxygenase-1 (COX-1) and COX-2, 5-lipoxygenase and
(LPO), 15-LPO, and interleukin- (IL-) 1β-induced prosta-
glandin E2 (PGE2) in gingival cells. TCS was also shown to
suppress a wider range of inflammatory mediators including
IL-1β-induced prostaglandin I2 (PGI2) and arachidonic
acid, tumor necrosis factor (TNF)α-induced PGE2, phospho-
lipase A2 (PLA2), and COX [134]. Moreover, in a double-
blind crossover study, participants who used a mouthrinse
with added 0.15% TCS developed significantly less oral
erythematous lesions than those who used a TCS-free mou-
thrinse [135]. By then, the anti-inflammatory properties of
TCS were established and were widely accepted within the
scientific and medical communities.
TCS in prosthetic devices was found to have no influence
on the acute phase response [136], and only modest
differences were seen between TCS and stannous fluoride
dentrifice [137]. Nevertheless, TCS, when applied intracrevi-
cularly, improved clinical parameters of gingivitis [138]. In a
recent double-blind, randomized, crossover study, it was
concluded that TCS-containing toothpaste inhibits inflam-
mation in peri-implant tissue [139].
To date, elaborations on the anti-inflammatory nature
of TCS have been the focus of subsequent studies. Mustafa
et al. [140–142] identified IL-1β, interferon (IFN)γ, major
histocompatibility complex (MHC) class II, and PGE syn-
thase-1, as targets of TCS in human gingival fibroblasts. Of
note, studies to discern the subcellular localization of TCS
show preference for nuclear, as opposed to cytosolic, accu-
mulation. Although initial uptake was considerably higher
in the cytoplasm, a great proportion of cytosolic TCS was
eliminated after repeated washing, while nuclear retention
was observed [143]. This may explain the perturbed inflam-
matory signaling associated with TCS. Moreover, in primary
human oral epithelial cells, TCS attenuated LPS-induced
cytokine response including IL-8, IL-1α, and TNFα and
aggravated the antimicrobial response, which was mediated
through microRNA (miRNA) regulation of the toll-like
receptor (TLR) pathway [144]. The findings were also
reciprocated in cells derived from diabetic patients, with an
exaggerated TLR response [145]. It was revealed that TCS,
nevertheless, abrogated LPS-induced TLR response, again,
through regulating miRNAs (stimulating miR146a and
inhibiting miR155s).
In skin and leukocytes of mice topically treated with
TCS, alterations in inflammatory responses were mediated
through TLR4 [146]. Likewise, TCS downregulated para-
thyroid hormone- (PTH-) or PGE2-stimulated matrix
metalloproteinase-13 (MMP-13) expression in rat osteoblas-
tic osteosarcoma cells [147]. Since hyperactive MMP-13 is
implicated in periodontal disease, it was suggested that TCS
might have a protective role against oral inflammatory condi-
tions through its action on that enzyme, among others [148].
Interestingly, favorable results have been observed for
TCS against other inflammatory conditions including car-
diovascular disease and hidradenitis suppurativa [149, 150].
Moreover, the use of TCS-impregnated ureteral stents seems
to be a promising approach to combat urinary tract infec-
tions (UTI) and associated inflammation [151, 152]. Along
those lines, an increased urinary TCS was related to increased
serum IL-6 in pregnant women [92], pointing at a possible
pro- or anti-inflammatory role.
In a unique effort by Barros et al. [153], TCS modulation
of the inflammatory response in an ex vivo whole blood stim-
ulation assay was investigated. In that study, TCS inhibited
multiple inflammatory mediators induced by LPS, including
interleukins, most notably IL-1 & IL-6, IFNs, and colony-
stimulating factor (CSF) 2. Activation of type 1 T helper
lymphocytes was interrupted through the action of TCS on
CD70. In a related report, TCS also reduced the capacity of
natural killer (NK) lymphocytes to lyse chronic myelogenous
leukemia K562 cells [154]. Recently, chitosan-TCS particles
reduced the expression of IL-1β-induced Cox2 and Il6,
among other immune molecules in gingival fibroblasts
(Table 4) [155], showcasing the vast amenability of this anti-
microbial to nanoparticle manipulation.
Other in vivo studies on rodents and marine organisms
clarified further the immunomodulatory properties of TCS.
For instance, in mice subjected to an acute, systemic E. coli
infection, Sharma et al. [156] demonstrated that cotreatment
with TCS significantly reversed the damage caused by the
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5/15-LPO Downregulated by TCS
PGE2 Downregulated by TCS
PGI2 Downregulated by TCS
Arachidonic acid Downregulated by TCS
PLA2 Downregulated by TCS




IL-1β Downregulated by TCS
MHC II Cell surface proteins; adaptive immunity regulators Downregulated by TCS




Il1b Downregulated by TCS
Tlr6 Innate immunity receptor Upregulated by TCS




IL-1α Downregulated by TCS
TNFα Downregulated by TCS
miR146a
Transcriptional regulators of TLR response
Upregulated by TCS
miR155s Downregulated by TCS
Mouse skin and leukocytes




TLR4 Upregulated by TCS
Tlr1 Upregulated by TCS
Tlr2 Upregulated by TCS
Tlr6 Upregulated by TCS





IL-1β Sensitive to TCS
IL-8 Sensitive to TCS




TIMP-1 Downregulated by TCS





TNFα Upregulated by TCS
IL-6 Upregulated by TCS
Human whole blood leukocytes




Ifna2 Downregulated by TCS
Ifna4 Downregulated by TCS
Ifna8 Downregulated by TCS
Il-1f10 Downregulated by TCS
Il-1f5 Downregulated by TCS
Il-1f7 Downregulated by TCS
Il-1f8 Downregulated by TCS
Il-1f9 Downregulated by TCS
Il-6 Downregulated by TCS
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bacteria. Specifically, TCS prolonged survival; lessened
hepatic congestion, hemorrhage, and fatty changes; and
reduced blood liver enzymes, serum TNFα, and the severity
of bacteremia. In accordance with published data, TCS was
similarly immunosuppressive in aquatic mussels (M. gallo-
provincialis) and clams (R. philippinarum) [64, 65].
Contrary to the overwhelming evidence of the anti-
inflammatory function of TCS, a number of studies have
nonetheless identified a proinflammatory role by the antisep-
tic. For example, upon intratracheal instillation of TCS in
Sprague-Dawley rats, elevated total cell (TC) count, poly-
morphonuclear leukocytes (PMNs), total protein (TP),
LDH, TNFα, and IL-6 were observed in bronchoalveolar
lavage (BAL) fluid [83], which, except for TP, returned
to baseline levels 14 days after exposure. Consonantly, it
has also been demonstrated that TCS exacerbates
diethylnitrosamine-induced hepatocellular carcinoma in
C57BL/6 mice [103]. Likewise, TCS was very recently found
to increase Tlr4 expression to promote colitis and aggravate
colitis-related cancer in C57BL/6 mice [157].
It is evident from the wealth of information present that
TCS is a modulator of immune and inflammatory reactions.
The sum of data from in vitro and in vivo studies indicates
that TCS, on its own, is immunosuppressive. Nevertheless,
increasing evidence seems to suggest that in the presence of
an existing adverse condition, such as inflammation or
tumor, TCS further potentiates and worsens the eventual
outcome. Investigations into the molecular basis behind this
unique behavior are particularly warranted.
6. Genotoxicity and Carcinogenicity
Among the most important aspects of toxicological profiling
of compounds is their interaction with the molecule of life—
the DNA. Early efforts [42, 158] point at a possible role for
TCS in somatic mutations observed in mice. TCS also caused
a significant reduction in global DNA methylation in human
hepatocellular carcinoma HepG2 cells, a finding associated
with liver tumor [159]. Similarly, TCS caused a dose-
responsive increase in chromosomal aberrations in lung
fibroblast V79 cells, but not in ovary CHO cells, of the Chi-
nese hamster Cricetulus griseus [12]. In a comparative study
on Drosophila melanogaster using three mouthwashes,
namely, Cepacol® (0.05% cetylpyridinium chloride), Perio-
gard® (0.12% chlorhexidine digluconate), and Plax® (0.03%
TCS), it was concluded that only the ethanol content in
Cepacol®, but not other active ingredients, caused mitotic
recombination between homologous chromosomes [160].
On the other hand, TCS induced dose-responsive DNA dam-
age in hemocytes of the zebra mussel D. polymorpha [88],
and strand breaks in the digestive gland of U. tumidus mus-
sels [114]. A similar dose-dependent DNA damage was
also observed in the earthworm E. fetida [108, 109], but
not in E. andrei [161].
Comparing TCS to other toxicants in the larvae of fresh-
water insect Chironomus riparius, Martinez-Paz et al. [162]
found TCS, along with nonylphenol, to be the most potent
in causing DNA breakage. It was also noted that TCS, either






Il-11 Downregulated by TCS
Il-13 Downregulated by TCS
Il-25 Downregulated by TCS
Il-19 Downregulated by TCS
Il-21 Downregulated by TCS
Il-9 Downregulated by TCS
Cd70 Cell surface receptor/ligand; activated lymphocytes Downregulated by TCS
Bmp2
Growth factors; bone and cartilage development
Upregulated by TCS
Bmp6 Upregulated by TCS




Gdf2 Downregulated by TCS
Gdf5 Downregulated by TCS
Gdf9 Downregulated by TCS
Inhba Hypothalamus-pituitary axis regulator Downregulated by TCS
Lefty2
Left-right determination factor 2;






IL-6 Upregulated by TCS
Abbreviation: MCP: monocyte chemoattractant protein; TIMP: tissue inhibitor of metalloproteinase; Bmp: bone morphogenetic protein; Gdf: growth
differentiation factor; Inhba: inhibin beta A chain.
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damage in D. magna [163]. Using the brine shrimp Artemia
salina, a time-dependent pattern of TCS-induced genotoxi-
city was identified [164]. Moreover, TCS was genotoxic in
the catfish Heteropneustes fossilis, goldfish C. auratus, and
rainbow trout O. mykiss [117, 118, 124]. Importantly, when
TCS at an environmentally relevant concentration (3 nM)
was treated to the freshwater protozoan Tetrahymena ther-
mophila, notable DNA damage, without significant perturba-
tion in growth or cell viability, was evident [165]. In a more
detailed study on E. coli, Gou et al. [55] revealed that the
electro-Fenton transformation of TCS caused upregulation
of a host of genes involved in the DNA repair machinery,
indicative of DNA stress. These genes belong to base excision
repair (mutT and nfo), nucleotide excision repair (uvrA and
uvrD), mismatch repair (uvrD and ssb), and double-strand
break repair (ssb and recN). Chromosomal stickiness,
reduced mitotic activity, and ana-telophase bridges were
also noticeable in the bulb onion Allium cepa following
TCS treatment [166].
In a recent proof-of-concept study, the promising
potential of a toxicogenomic approach as a follow-up to
positive in vitro genotoxicity data was evaluated. Using TCS
as a testing compound, it was shown that the antimicrobial
is non-DNA reactive and that it is genotoxic solely in vitro
as opposed to in vivo [167].
Ambiguity surrounding the carcinogenicity of TCS still
remains today. Investigators have generally been able to pro-
vide evidence for carcinogenic effects in animal models but
not in humans. Of the earliest studies in this regard was a
report by Lyman and Furia [38] identifying TCS as a carcin-
ogen in mice. Other studies on mice have been in agreement
with that conclusion. For example, it was noted that chronic
TCS exposure increased the incidence of liver neoplasms [12]
and aggravated hepatocellular carcinoma [103]. Further-
more, TCS caused colonic inflammation and worsened colitis
or tumorigenesis induced by dextran sodium sulfate [168].
These findings, were, however, not paralleled in rats, ham-
sters, or baboons [12, 169]. More importantly, in vivo human
studies of TCS are scarce, and aspects related to TCS-induced
oncogenesis are lacking. Consequently, whether TCS poses a
carcinogenic hazard to humans is unknown and requires fur-
ther investigation. Nonetheless, the interaction of TCS with
human-derived cancer cells in vitro has recently gained con-
siderable attention (reviewed under Therapeutic Proposals).
In light of available data (Table 5), TCS demon-
strates carcinogenicity solely in mice and within a nar-
row range of tissues (the liver and colon), which constitutes
limited evidence of carcinogenicity according to ECHA
(https://echa.europa.eu/documents/10162/23036412/clp_en.
pdf/58b5dc6d-ac2a-4910-9702-e9e1f5051cc5). Hence, TCS
is not classifiable as a carcinogen (http://ec.europa.eu/
health/scientific_committees/consumer_safety/docs/sccs_o_
054.pdf). It must be noted that in case future assessment
conclusively rules out TCS as a human carcinogen, caution
with its use must still be exercised given the established
carcinogenicity of its transformation products—dioxins,
chloroform, and anilines [170].
7. Cellular Signaling
Adaptations to the ever-changing intracellular and sur-
rounding environments are achieved, in large part, by
effective communication. Transmission of information that
carries specific instructions is executed by messengers that
function in tandem within a defined pathway. Tasks, how-
ever, are usually accomplished through the sequential trans-
duction of multiple messages along a complex, intertwining
network that involves a wide assortment of mediators
[171]. Hence, the participation of cell signaling cascades in
the response to xenobiotics cannot be overlooked.
Table 5: TCS genotoxicity and carcinogenicity.
Model Effect Classification
HepG2 cells Global DNA hypomethylation
Limited evidence of carcinogenicity
V79 cells Chromosomal aberrations
Mouse
Somatic mutation (positive spot test)
Increased incidence of liver tumors
Aggravated hepatocellular carcinoma
Exacerbated colon tumorigenesis
D. polymorpha DNA damage (positive comet assay)
N/A
U. tumidus DNA strand breaks (Hoescht 33342 fluorescence)
E. Fetida DNA damage (positive Comet assay)
D. magna DNA damage (positive Comet assay)
A. salina DNA damage (positive Comet assay)
H. fossilis DNA damage (positive Comet assay)
C. auratus DNA damage (positive Comet assay)
O. mykiss DNA damage (positive Comet assay)
T. thermophila DNA damage (positive Comet assay)
A. cepa
Chromosomal stickiness, reduced mitotic activity, and ana-telophase bridges
(positive Feulgen reaction)
N/A = data from non-mammalian animals are not considered for ECHA mutagenicity/carcinogenicity classification.
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The use of human cell lines has provided a wealth of
information particularly regarding the study of signaling
molecules responsive to stressors and xenobiotics, including
TCS. In H460 lung cancer cells, TCS promoted migration
and invasion through focal adhesion kinase/ATP-dependent
tyrosine kinase (FAK/Akt) and Ras-related C3 botulinum
toxin substrate 1 (Rac1) [72]. Evidence similarly exists for
the classical mitogen-activated protein kinases (MAPK) as
targets of TCS. For example, proliferation of JB6 Cl 41-5a
cells as induced by TCS was accompanied by activation of
extracellular signal-regulated kinases 1/2 (ERK1/2), c-Jun
N-terminal kinases (JNK), and p38 MAPKs, in addition to
Akt [84]. Importantly, blocking either MEK1/2 or phosphoi-
nositide 3-kinase (PI3K) significantly attenuated TCS-
induced proliferation. In another study on rat neural stem
cells, TCS-induced cytotoxicity and apoptosis were accompa-
nied by activation of p38 and JNK and suppression of ERK,
Akt, and PI3K [79]. This points at the involvement of these
proteins in both cellular survival and death as brought about
by TCS. Recently, TCS was shown to activate p38 and JNK
in vivo as detected in the hypothalamus of Sprague-Dawley
rats and in vitro utilizing human Nthy-ori 3-1 thyroid follic-
ular cells [97]. In that study, TCS stimulated the thyrotropin-
releasing hormone receptor through p38 MAPK, which, in
turn, influenced the thyroid peroxidase (TPO) level.
In suppressing TLR signaling in whole blood leukocytes,
TCS downregulated the expression of several signaling
mediators, most notably, NF-κB-inducing kinase (Nik) and
C-jun, which accounted for the overall blunted inflammatory
response to LPS in these cells [153]. Furthermore, suppres-
sion ofMmp-13 expression in mouse osteoblastic osteocarci-
noma cells by TCS was possibly related to its inhibition of
Fos/Jun and AP-1 sequence binding in both the Mmp-13
and C-fos promoters [147].
The endocrine-disrupting activity of TCS, specifically its
estrogenicity, has been of great interest to researchers. Kim
et al. [73] utilized BG-1 ovarian cancer cells to show that
the proliferative effects of TCS were mediated through ERα.
Confirming the ER’s role, the use of ICI 182,780 reversed
the proliferative properties of TCS along with associated
perturbations in cyclin D1, p21, and Bax expression and pro-
tein levels. Likewise, the ER is implicated in TCS-induced
proliferation of MCF-7 cells and increased breast tumor mass
in mice [74, 75, 172]. This was similarly indicated by TCS
inhibition with ICI 182,780 or kaempferol and the stimula-
tion of insulin-like growth factor (IGF) signaling, namely,
phosphorylated insulin receptor substrate (pIRS-1), pAkt,
pMEK1/2, and pERK1/2 [75]. Notably, kaempferol also
inhibited TCS-induced VM7Luc4E2 cell growth [76]. These
observations are in congruence with an earlier report by
Huang et al. [173] describing the estrogenic activities of
nanomolar concentrations of TCS in the same cells. Inves-
tigating ER-responsive genes on the transcriptional and
translational levels, it was shown that TCS induced pS2
but blunted ERα mRNA and protein levels, the latter of
which was related to elevated miR-22, miR-206, and
miR-193b miRNAs.
Recent studies have also argued for the dual effect of TCS
on ER signaling. For example, Henry and Fair [174]
demonstrated that, when administered alone to MCF7 cells,
TCS at 7 nM to 700μM exhibits estrogenic activity but
becomes antiestrogenic in the presence of E2. Along those
lines, it was shown that TCS, on its own, lacked any effect
on rat uterine growth, but could still potentiate the effect of
ethinylestradiol (EE) [175]. In a follow-up investigation, it
was reported that TCS promotes EE-induced inhibition of
ERα and ERβ expression and when given alone does not acti-
vate ER at concentrations from 30nM to 100μM [176]. Fur-
thermore, TCS diminished E2 and estrogen sulfotransferase
in sheep placenta [177]. This is in contrast to the increased
activity of ERβ but not ERα caused by a TCS-derivative mix-
ture, which led to neurological and behavioral abnormalities
in zebrafish [87]. Also, Sprague-Dawley rats given TCS
showed increased uterine weight and Calbindin-d(9k)
(CaBP-9k) expression, which was also reciprocated in pitui-
tary GH3 cells [178]. Reversal of both anomalies by ICI
182,780 and RU 486 points at a possible estrogenic role of
the antimicrobial.
Very recently, Serra et al. [179] challenged accumulating
evidence of TCS estrogenicity by showing the lack of agonis-
tic or antagonistic effect in vivo and in vitro. While up to
0.3μM TCS did not modulate ER-dependent brain aroma-
tase in zebrafish embryos, interference with the enzyme’s
activity, and with E2 activation of the enzyme observed at
1μM, was not attributed to TCS-ER interaction. Moreover,
up to 10μM TCS lacked estrogenic effects in ER-expressing
zebrafish liver cells as well as in MCF-7 cells [179]. Addition-
ally, in a screening study of the estrogenicity of a group of
endocrine-disrupting chemicals on fish species, TCS failed
to significantly elicit a response in an in vitro ERα reporter
gene assay [180].
In light of available evidence, the general consensus
seems to indicate that the estrogenicity of TCS is contingent
upon multiple factors, including concentration, species,
duration of exposure, and whether TCS is administered alone
or in combination with other molecules.
With regard to the androgenic properties of TCS, it was
revealed that TCS interferes with testosterone- (TSN-)
related transcription but promotes that dependent on andro-
gen [181, 182]. In a recent in vivo study on weanling male
rats, Riad et al. [104] reported that TCS, either alone or
combined with butylparaben, reduced TSN, leutinizing hor-
mone (LH), and follicle-stimulating hormone (FSH), while
increased E2 was observed upon single TCS administration
Also, TCS-induced proliferation and migration of LNCaP
cells were significantly reduced in presence of bicalutamide,
an androgen receptor (AR) antagonist [77]. These findings
support a previous report by Ahn et al. [183] in which
1μM TCS reduced E2-induced ER activation by 50% and
AR in human BG1Luc4E2 ovarian adenocarcinoma cells
and T47D-ARE breast cancer cells, respectively. Evidence
for TCS estrogenicity was detected in MCF7 cells when
[(3)H]estradiol was successfully displaced from the ER by
the antimicrobial [184]. Furthermore, 10μMTCS attenuated
E2-dependent ERE-CAT reporter gene induction, while 0.1
and 1μM TCS inhibited TSN-stimulated LTR-CAT
reporter gene in both T47D cells and S115 mouse mammary
tumor cells [184]. TCS was also determined to have a weak
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effect on AhR in recombinant rat hepatoma (H4L1.1c4) cells.
Finally, Forgacs et al. [185] showed that TCS interferes with
recombinant hCG stimulation of TSN in a novel BLTK1
murine Leydig cell model. Most recently, however, no signif-
icant influence on androgen synthesis or activity by TCS was
observed in Wistar rats [186].
Controversy surrounding the interaction between TCS
and members of the peroxisome proliferator-activated recep-
tors (PPARs) has gained considerable attention as of late.
This has essentially stemmed from the apparent discrepancy
between data obtained from humans and those from rodents.
In comparing the differential modulation of TCS on PPARα
in HepG2 cells and mouse hepatoma Hepa1c1c7 cells, dis-
tinct responses were observed by Wu et al. [187]. Protein
levels of PPARα downstream target, acyl-coenzyme A oxi-
dase, were decreased in HepG2 cells but were increased in
Hepa1c1c7, which also showed higher DNA synthesis and
blunted apoptosis through transforming growth factor
(TGF-β). PPAR signaling was similarly identified as a target
of TCS through genome-wide CRISPR-Cas9 screening in
HepG2 cells [188], zebrafish [189], and Gallus gallus
chicken embryos [190]. In the latter model, PPAR signal-
ing members Cyp7a1, fatty acid-binding protein 1 (Fabp1),
acyl-CoA synthetase long-chain family member 5 (Acsl5),
acyl-CoA oxidase 2 (Acox2), and perilipin 1 (Plin1) were
upregulated, whereas angiopoietin-like 4 (Angptl) was
downregulated.
TCS administered to pregnant mice caused insulin
resistance, hypothyroidism, diminished glucose transporter
4 (GLUT4) expression, and inhibition of Akt and mTOR
phosphorylation [191, 192]. While thyroxine corrected these
adversaries, PPARγ activator, rosiglitazone, solely reversed
the decrease in Akt phosphorylation in adipose tissue and
in muscle [192]. PPARγ is known to ameliorate mTOR
suppression-induced glucose intolerance in rats [193],
further underlining the far-reaching effects of TCS action.
Although TCS has been reported to promote hepatocyte
proliferation in mice through PPAR [12], Yueh et al. [103]
found no appreciable induction of PPARα following TCS
treatment. Importantly, the authors also identified constitu-
tive androstane receptor (CAR) as a possible aggravator of
TCS-induced tumorigenesis, given the halved tumor number
in Car–/− mice compared to their Car+/− counterparts. TCS,
as is the case with PPARs, is reported to exhibit varying affin-
ities for CAR and pregnane X receptor (PXR) in humans and
rodents. A weak agonist for human CAR, TCS was found to
be a reverse agonist for rodent CAR, an agonist for human
PXR, and had no effect on rodent PXR [194].
Calcium concentration within cells influences protein
conformation and dynamics. Protein binding of Ca2+, on
the other hand, maintains the ion’s content within a physio-
logical range and sets forth diverse cellular activities related
to gene expression, motility, secretion, and survival [195].
Beside proteins, intracellular Ca2+ levels are modulated by a
variety of stimuli, including xenobiotic exposure. Through
the Ca2+ channel ryanodine (Ry) receptor type 1 (RyR1),
TCS increased cytosolic Ca2+ dose-dependently in primary
skeletal myotubes irrespective of extracellular Ca2+ [183].
Accordingly, muscle contractility was compromised upon
TCS exposure in vitro and in vivo [196]. Results from this
study indicate that TCS impaired excitation-contraction
coupling (ECC) in cardiac and skeletal muscles and
enhanced electrically induced Ca2+ transients in myotubes
without depleting intracellular Ca2+ and notwithstanding
RyR1 blockage. TCS also efficiently blocked excitation-
coupled Ca2+ entry and interfered with the bidirectional
signaling between RyR1 channels and Ca2+ ions. Likewise,
TCS compromised ECC in larval fathead minnows Pime-
phales promelas, as evidenced by altered RyR and dihydro-
pyridine receptor (DHPR) mRNA and protein levels and
weakened ligand binding to both receptors in adult muscle
homogenates [197].
In rat thymocytes, TCS elevated intracellular Ca2+ levels
and opened Ca2+-responsive K+ channels, eventually leading
to membrane hyperpolarization [198]. Also, TCS prevented
Ca2+-induced mitochondrial swelling in rat liver [199]. A
more in-depth analysis of TCS modulation of Ca2+ homeo-
stasis was conducted on rat basophilic leukemia (RBL) mast
cells [24]. In this cell type, TCS caused mitochondrial fission
and diminished membrane potential and translocation, with
compromised ATP production and elevated ROS. These
changes were associated with perturbed mitochondrial
and endoplasmic reticulum Ca2+ and depleted cytosolic
Ca2+ levels following antigen stimulation. Accordingly,
TCS-induced degranulation of mast cell may at least in part
be attributed to Ca2+ mobilization.
Calcium modulation by TCS has also been investigated
in other organisms. In C. reinhardtii exposed to 14μM
TCS, increased Ca2+ levels with oxidative stress, cell and
mitochondrial membrane depolarization, compromised
photosynthesis, and caspase activation were noted [90].
Importantly, chelation of intracellular Ca2+ ions by
BAPTA-AM protected the algae from TCS-induced Ca2+
dysregulation. These observations strongly implicate Ca2+
as a mediator of a wide array of toxic anomalies attributed
to TCS.
Literature concerning the xenobiotic response to TCS has
revealed important signaling pathways activated or sup-
pressed by TCS (Table 6). Distinct outcomes exist among
species and even within the same species based on experi-
mental conditions and model under investigation. Although
important milestones in TCS signaling have been achieved
so far, there remains a lot to be discovered, especially in
human-based systems, about the modulatory effects of TCS
on cellular physiology. In particular, the response of many
human cell types and tissues to TCS treatment is unknown,
and identification of signaling pathways and their roles
in cellular growth, metabolism, and overall function is
therefore advised.
8. Therapeutic Proposals
The first specific action mechanism of TCS in prokaryotes
was only demonstrated 20 years ago, when inhibition of fatty
acid synthesis in Escherichia coli was noted following
exposure to TCS [200, 201]. TCS irreversibly inhibited the
fatty acid biosynthesis enzyme, enoyl–acyl carrier protein
reductase (ACP), by mimicking its natural substrate in vivo.
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p38 Upregulated by TCS
Akt Upregulated by TCS
PI3K Upregulated by TCS





















Cjun Downregulated by TCS
Mouse osteoblastic osteocarcinoma
Fos Downregulated by TCS
Jun Downregulated by TCS





ERα∗ Sensitive to TCS
pIRS-1 Upregulated by TCS
pAKT Upregulated by TCS
pMEK1/2 Upregulated by TCS
pERK1/2 Upregulated by TCS
VM7Luc4E2 cells
Erα Downregulated by TCS
Ps2 Upregulated by TCS
ERα Downregulated by TCS
pS2 Upregulated by TCS
miR-22 Upregulated by TCS
miR-206 Upregulated by TCS





Estrogen sulfotransferase Downregulated by TCS
BG1Luc4E2 cells ER∗ Downregulated by TCS
Sprague-Dawley rats and GH3 cells CaBP-9 k Estrogenicity Upregulated by TCS
LNCaP AR Androgenicity; cell proliferation, and migration Upregulated by TCS
T47D-ARE cells AR Anti-androgenicity Downregulated by TCS
H4L1.1c4 cells AR Pro(anti)-androgenicity Sensitive to TCS
HepG2 cells Acyl-coenzyme A oxidase Blunted lipid metabolism Downregulated by TCS
Hepa1c1c7 cells
Acyl-coenzyme A oxidase Enhanced lipid metabolism and DNA synthesis Upregulated by TCS





PPARγ Upregulated by TCS
G. gallus embryo livers PPARα Upregulated by TCS
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Further, a mutated or overexpressed ACP, encoded by fabI,
was shown to confer TCS resistance in the bacterium. These
findings established ACP as a specific, subcellular TCS target.
Efforts have thus far revealed the susceptibility of a host of
other pathogens to inhibition of fatty acid synthesis by
TCS. These include Staphylococcus aureus, M. tuberculosis,
Helicobacter pylori, Haemophilus influenzae, Plasmodium
falciparum, Toxoplasma gondii, Leishmania spp., and Trypa-
nosoma spp. [52, 202–208]. In humans, fatty acid synthase
(FAS) is the only multienzyme complex that is responsible
for the endogenous synthesis of saturated fatty acids from
acetyl-CoA and malonyl-CoA [209, 210]. Although a BLAST
analysis of E. coli FabI protein and FAS showed no
homology, appreciable sequence similarities were neverthe-
less found with polyketide synthase and type I FAS of M.
tuberculosis [211].
The success of cerulenin, a mycotoxin with fatty acid
inhibitory action, in suppressing tumor progression in vivo
has spawned several reports in support of fatty acid synthesis
inhibition as an emerging target for chemotherapy [212].
The earliest study in this regard investigated the cytotoxicity
of TCS in MCF-7 and SKBr-3 breast cancer cells [211]. It
was revealed that TCS at 10-50μM is cytotoxic and antipro-
liferative, induces morphological alterations, and inhibits
FAS. These findings corroborate an earlier observation link-
ing FAS inhibition with apoptotic death of breast cancer
cells [211, 213, 214]. TCS was similarly found to inhibit
the development of methylnitrosourea-induced breast can-
cer in Sprague-Dawley rats [209]. In human A-375 mela-
noma cells, TCS inhibited growth at 40μM [215]. TCS
was similarly found to be dose-dependently proapoptotic
in prostate cancer cells, with IC50 values as low as 4.5-
7.8μM [216]. Whereas no cytotoxicity was observed in
NIH3T3 fibroblasts at concentrations up to 60μM, values
of IC50 ranging from 0.74 to 62μM were nonetheless
observed in nonmalignant prostate cells. This suggests
two things; first, that prostate cells are relatively more sen-
sitive to TCS toxicity than fibroblasts and presumably
other nonmalignant cell types, and second, that malignant
prostate cells exhibit higher chemosensitivity compared to
their nonmalignant counterparts. This differential suscepti-
bility could be due to overexpressed FAS in malignant
cells. However, in contrast to these reports, at concentra-
tions up to 345μM, TCS was found to be preferentially
cytotoxic to Y79 RB cells over mouse 3T3 fibroblasts and
human MIO-M1 Müller glial cells as indicated by IC50
values, creating a large therapeutic index of 7.1 and 5.3,
respectively [217]. FAS suppression, depleted fatty acid
content, lipid peroxidation, and apoptotic death were
noted in Y79 RB cells at the same TCS concentration
range [98]. Recently, TCS at 40μM was also shown to
be effective against MiaPaCa-2 and AsPC-1 pancreatic
cancer cells suppressing proliferation and eliciting apopto-
tic death [218]. Of note, in a related study, TCS impeded
mouse preadipocyte differentiation [219]. Given the regu-
lation of food intake by FAS, and the susceptibility of adi-
pocyte development to TCS inhibition, it was suggested
that TCS may possess anti-obesogenic properties.
The differential expression and activity of FAS in
healthy and malignant tissues, where it is upregulated in
the latter [220, 221], indicate a possibly high therapeutic
index. The long history of human use, and the ubiquity
of TCS in consumer products, coupled with encouraging
in vivo results, cements the antimicrobial as a promising
candidate for chemotherapy. As noted earlier, it must be
stressed that variations in the final outcome of TCS treat-
ment largely depend on experimental setup. Moreover,
limited data from animal studies suggest that in the pres-
ence of a preexisting tumor, TCS administration seems to
exacerbate the condition. This observation is concerning
and indeed warrants further investigation before TCS
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RyR1 Upregulated by TCS
P. promelas muscle homogenates
Ryr2 Sensitive to TCS
Ryr3 Downregulated by TCS
RyR Downregulated by TCS
Rat thymocytes Ca2+ Cell membrane hyperpolarization Upregulated by TCS
RBL cells Ca2+ Mast cell degranulation Downregulated by TCS
C. reinhardtii Ca2+ Dampened photosynthesis Upregulated by TCS
∗TCS is anti-estrogenic in the presence of E2.
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9. Conclusion
TCS is a synthetic antimicrobial with a long history of human
use. At concentrations well below those present in commer-
cial products, data from in vitro and in vivo studies have
provided evidence of adverse effects on diverse molecular
pathways. Most alarmingly is TCS enhancement of malig-
nant cell proliferation in vitro and tumor growth in vivo.
On the other hand, TCS has also been shown to be protective
against malignant cell growth and proliferation, possibly
opening the door for its use in chemotherapy. Clearly, dose
and time dependence is an important factor in determining
the eventual denouement of the chemical. In spite of the
numerous publications dissecting the signaling pathways
responsive to TCS, it is evident that a severe paucity
surrounding human-based in vivo and in vitro studies still
remains today. Future studies, thus, should focus on identify-
ing signaling molecules differentially regulated by TCS and
characterize their roles in toxic or protective effects in differ-
ent cell types. Insights gained from such revelations will be
invaluable to possibly validate targets for drug development
or devise possible TCS adjuvants or inhibitors.
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